602 related articles for article (PubMed ID: 26351341)
1. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Sacco AG; Cohen EE
J Clin Oncol; 2015 Oct; 33(29):3305-13. PubMed ID: 26351341
[TBL] [Abstract][Full Text] [Related]
2. Current treatment options for metastatic head and neck cancer.
Price KA; Cohen EE
Curr Treat Options Oncol; 2012 Mar; 13(1):35-46. PubMed ID: 22252884
[TBL] [Abstract][Full Text] [Related]
3. Current status of systemic therapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Jacob LA; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2016; 53(4):471-477. PubMed ID: 28485332
[TBL] [Abstract][Full Text] [Related]
4. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma.
Markovic A; Chung CH
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1149-59. PubMed ID: 23098115
[TBL] [Abstract][Full Text] [Related]
5. Systemic Treatment in HPV-Induced Recurrent or Metastatic HNSCC.
Rieke DT; Keilholz U
Recent Results Cancer Res; 2017; 206():149-160. PubMed ID: 27699536
[TBL] [Abstract][Full Text] [Related]
6. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
Azoury SC; Gilmore RC; Shukla V
Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
[TBL] [Abstract][Full Text] [Related]
7. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
Specenier P; Vermorken JB
Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
[TBL] [Abstract][Full Text] [Related]
8. Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy.
de Andrade DA; Machiels JP
Curr Opin Oncol; 2012 May; 24(3):211-7. PubMed ID: 22498572
[TBL] [Abstract][Full Text] [Related]
9. Expanding role of the medical oncologist in the management of head and neck cancer.
Choong N; Vokes E
CA Cancer J Clin; 2008; 58(1):32-53. PubMed ID: 18096865
[TBL] [Abstract][Full Text] [Related]
10. [Therapy of recurrent or metastatic head and neck squamous cell carcinoma : highlights of the ASCO Meeting 2014].
Zeller N; Busch CJ; Schafhausen P; Knecht R; Möckelmann N
HNO; 2014 Nov; 62(11):787-92. PubMed ID: 25298331
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for recurrent/metastatic head and neck cancer.
Alfieri S; Cavalieri S; Licitra L
Curr Opin Otolaryngol Head Neck Surg; 2018 Apr; 26(2):152-156. PubMed ID: 29432222
[TBL] [Abstract][Full Text] [Related]
12. Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer.
Fury MG; Pfister DG
J Natl Compr Canc Netw; 2011 Jun; 9(6):681-9. PubMed ID: 21636539
[TBL] [Abstract][Full Text] [Related]
13. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Cohen EE
J Clin Oncol; 2006 Jun; 24(17):2659-65. PubMed ID: 16763280
[TBL] [Abstract][Full Text] [Related]
14. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
Fakhry C; Westra WH; Li S; Cmelak A; Ridge JA; Pinto H; Forastiere A; Gillison ML
J Natl Cancer Inst; 2008 Feb; 100(4):261-9. PubMed ID: 18270337
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy: A novel approach in head and neck cancer.
Christy AW; Bojan A
Indian J Dent Res; 2013; 24(2):261-6. PubMed ID: 23965459
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
[TBL] [Abstract][Full Text] [Related]
18. Targeting angiogenesis in head and neck cancer.
Vassilakopoulou M; Psyrri A; Argiris A
Oral Oncol; 2015 May; 51(5):409-15. PubMed ID: 25680863
[TBL] [Abstract][Full Text] [Related]
19. Systemic Therapy for Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.
Colevas AD
J Natl Compr Canc Netw; 2015 May; 13(5):e37-48. PubMed ID: 26158134
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
Sheth S; Weiss J
Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
